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Abstract 
Introduction: Bronchial artery embolisation (BAE) is one of the methods used in massive and recurring haemoptysis. The aim of 
the study is to determine the effectiveness and complications of bronchial artery embolisation in recurring haemoptysis. 
Material and methods: The analysis included 47 embolisation procedures performed on 30 patients treated between 2011 and 
2017 in the Department of Respiratory Medicine, Allergology and Pulmonary Oncology due to haemoptysis. The patient’s age ranged 
between 18 and 71 years, while mean age at the time of BAE was 33.5 years. Patients with tuberculosis constituted 73.33% (n = 22) 
of the sample and underwent 31 embolisation procedures in total. The remaining part of the sample (n = 8) collectively underwent 16 
BAEs. The analysis was conducted by verifying the medical documentation, as well as carrying face-to-face and phone conversations. 
Results: Immediate control due to the inhibition of bleeding was obtained in 95.75% of cases. Recurrence within 3 days of BAE 
was reported in 5 patients (10.63%), and 4 re-embolisation procedures were conducted. In 10 patients (33.33%), recurrence 
was observed during the first year post-BAE, while it was reported in 17 cases during the whole observation period (56.66% of 
patients). The subjects who underwent re-embolisation demonstrated recurrence-free periods lasting from 2 days to 63 months. 
In patients with recurrence but no re-embolisation, the shortest and longest haemoptysis-free time was 2 and 35 months, respec-
tively. Eleven patients (36.66%) required several embolisation procedures during the whole observation period.
Conclusions: BAE is a highly successful procedure in treating haemoptysis. The risk of complications is low.
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Introduction
Haemoptysis stands for coughing up of blood 
or bloody sputum from the lower parts of the 
respiratory tract, i.e. from the trachea or bronchi. 
The loss of < 200 ml during 24 h does not require 
surgical intervention. However, coughing up more 
than 200 ml daily means massive haemoptysis 
and can be directly life-threatening, which calls 
for endovascular treatment [1, 2]. 
Bronchial artery embolisation (BAE) is one of 
the methods used in massive haemoptysis [3–5]. 
Vascular haemorrhage is a common complication 
in chronic lung diseases [6]. It can be triggered by: 
cystic fibrosis [2], lung cancer [7], tuberculosis [4], 
bronchial and lung inflammations, mycotic infec-
tions, as well as congenital defects of pulmonary and 
cardiac vessels [8]. In the majority of patients, hae-
moptysis is a complication of destructive changes 
occurring in bronchial vessels as a result of chronic 
inflammation in the course of diseases listed above 
[1, 2]. This leads to arterial widening and the de-
velopment of collateral circulation, characterised 
by fragile, sinuous vessels that can break easily [9]. 
The aim of the paper is to present the results 
of a  retrospective analysis of the effectiveness 
of bronchial artery embolisation (taking com-
plications into account) in the Department of 
Respiratory Medicine, Allergology and Pulmonary 
Oncology, during the period from 2011 to 2017. 
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Material and methods
30 patients were treated in the Department 
by means of endovascular embolisation between 
2011 and 2017. BAE was conducted due to mas-
sive and/or recurring haemoptysis. Most of the pa-
tients were previously treated by means of other 
methods, including pharmacological treatment, 
which failed to stop haemoptysis.
In the paper, we report on the analysis of 
embolisation conducted on different patients, ir-
respective of haemoptysis aetiology. Patients with 
cystic fibrosis constituted 73.33% (n = 22) of the 
sample, and collectively underwent 31 embolisa-
tion procedures. The remaining part of the sample 
(n = 8, 26.7%) was composed of patients with: 
pulmonary aspergillosis (n = 3), silicosis (n = 1), 
right lung hypoplasia (n = 1), lung fibrosis sub-
sequent to mediastinal seminoma radiotherapy 
(n = 1), pulmonary mycobacteriosis (n = 1) 
and bronchiectasis (n = 1). Sixteen embolisation 
procedures were performed. 
The patients underwent embolisation at the 
Department of Respiratory Medicine, Allergolo-
gy and Pulmonary Oncology, following diligent 
clinical assessment. The planned angiographic 
procedure was preceded by CT angiography scan 
(CT-angio scan), in order to assess pulmonary 
parenchyma, especially the number, anatomy and 
anatomical variety of bronchial arteries. Due to its 
high sensitivity and specificity, CT angiography is 
a method of choice in diagnosis of heamoptisis. 
It’s helpful in diagnosis of bleeding localisation 
and its cause, and has a significant impact on de-
ciding further therapeutic options. Efficacy in de-
termining bleeding site is estimated at 63–100%. 
Given CT angiography short duration, it may be 
only diagnostic possibility in urgent emergency, 
which massive haemoptysis often is [10–12].
Individuals with cystic-fibrosis-induced hae-
moptysis had all bronchial arteries that could be 
subject to embolised catheterisation . In the rest 
of patients, embolisation was conducted for only 
those arteries which led to the area suspected to 
be the source of haemorrhage, based on bronchos-
copy and CT-angio scan. 
Common femoral artery access was used 
as the route in BAE procedures. Pathologically 
changed vessels were identified by means of 
digital subtraction angiography (DSA), conduct-
ing a preliminary descending aorta aortogram 
(Fig. 1). Subsequently, bronchial branches were 
selectively catheterised by means of 4F or 5F 
catheters. Embolisation was conducted using 
polyvinyl alcohol (PVA) embolisation particles 
Figure 1. Pathologically changed vessels identified by means of digital 
subtraction angiography (DSA), conducting a preliminary descending 
aorta aortogram
Figure 2. Embolisation conducted using polyvinyl alcohol (PVA) embo-
lisation particles (Cook) whose size was 300 to 2000 µm
(Cook) whose size was 300 to 2000 µm (Fig. 2). 
In addition, a microcatheter was introduced in 
the case the regular catheter was unstable, or 
when embolisation liquids (Squid) or detachable 
spirals were used.
The number of patients who underwent 
embolisation by means of PVA was equal to 28 
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(mean age: 33 yo, range: 18–71 yo). In addition, 
there was 1 patient (26 yo) in whom embolisation 
spirals were used. Finally, also 1 patient (36 yo) 
was subjected to different BAE methods: first, 
a procedure with detachable spirals and Squid , 
which was followed 6 days later by PVA embo-
lisation. 
Results
Thirty patients with recurring and/or massive 
haemoptysis required bronchial artery embolisa-
tion. The average time of observation was 22.8 
months, and ranged from 5 days to 84 months. 
Contact with 3 patients was lost immediately 
after hospitalisation during which embolisation 
was conducted. Another 5 patients discontinued 
the contact during the observation period (mean 
time from BAE to contact loss: 23 months, ranging 
from 5 to 52 months). 
Immediate haemorrhage inhibition during the 
first 24 hours post-embolisation was achieved in 
95.75% of patients (haemoptysis recurred within 
several hours in two patients). Haemoptysis re-
currence within 3 days post-BAE was observed in 
5 patients (10.63%). Four re-embolisation proce-
dures were conducted during the same hospital stay. 
Haemoptysis recurred within the first year post-em-
bolisation in 10 patients (33.33%), and in 17 patients 
(56.66%) during the total period of observation.
Eleven out of 17 patients (64.71%) with re-
curring haemoptysis required another endovas-
cular bronchial artery embolisation procedure. 
Eight of those patients had two embolisation 
procedures, 1 patient — three, 1 patient — four, 
and another 1 patient — five embolisation pro-
cedures performed. In total, 28 BAEs (17 re-em-
bolisation procedures) were conducted in those 
patients. The remaining 6 patients experienced 
minor haemoptysis which stopped following 
conservative treatment. 
Three patients underwent lung transplant 
surgery during the observation period. The aver-
age time between the last BAE and lung transplant 
was 15 months, ranging from 3 to 28 months. 
Pneumonectomy of the right lung was per-
formed in one patient 2 months following the 
last BAE. 
Six patients died during the observation, 
including 5 patients with cystic fibrosis and 
1 patient with pulmonary mycetoma. The average 
time between the last BAE and patient’s death 
was 16.5 months, ranging from 3 to 38 months.
The number of embolisation procedures goes 
as follows for different methods: 45 (95.74%) 
embolisation procedures with PVA particles, 
1 (2.13%) spiral embolisation and 1 (2.13%) spiral 
+ Squid embolisation. The vast majority of BAEs 
(45 out of 47) was conducted by means of PVA 
particles, and therefore comparing this method 
to the other ones (2 out of 47 BAEs) would be 
inconclusive.
In order to determine the shortest and the 
longest haemoptysis-free period, patients were 
divided into three groups. The first group was 
composed of individuals in whom re-embolisa-
tion was performed due to massive haemoptysis 
(Table 1); the second group included patients 
with minor haemoptysis (blood-tinged sputum, 
coughing up single blood lines) who did not 
require any surgical intervention; in turn, the 
third group was composed of patients with no 
recurrence. 
11 individuals were present in the first 
group. The shortest bleeding-free interval was 
several hours while the longest one lasted 63 
months. The shortest recurrence-free period 
between the first and second BAE (11 proce-
dures, average time: 13 months) was equal to 
2 days, while the longest one was 63 months. 
The shortest recurrence-free period between the 
second and third BAE (3 procedures, average 
Table 1. Time between consecutive embolizations in patients with recurrent hemoptysis 
BAE/PT Pt 2 Pt 3 Pt 6 Pt 7 Pt 8 Pt 12 Pt 14 Pt 16 Pt 17 Pt 25 Pt 28
1–2 3 months 63  
months
22 
months
2 days 13 
months
10 
months
14 
months
10 
months
5 days 4 months 11 days
2–3 8 months 17 
months
11 days
3–4 16 
months
13 
months
4–5 5 days
BAE: bronchial artery embolization; Pt: patient
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time: 8 months) lasted 11 days, and the longest: 
17 months. The shortest recurrence-free period 
between the third and fourth BAE (2 procedures, 
average time: 15 months) was 13 months, while 
the longest one lasted 16 months. Finally, in one 
patient, a fifth BAE was performed five days after 
the fourth one. 
Six patients were included in the second 
group. The shortest recurrence-free period was 
2 months, and the longest one: 35 months. 
Patients in whom recurrence did not occur 
were under observation from 5 to 38 months.
In general, haemoptysis-free time averaged 
for all 30 patients was equal to 15.8 months.
Minor post-BAE complications reported by 
the patients included haematoma at the site of 
microcatheter insertion (n = 1), fever (n = 1) and 
vomiting (n = 2).
The patients’ data, information on emboli-
sation, haemoptysis-free period, other medical 
incidents and the death of observed patients are 
presented in Table 2.
Discussion
While all the procedures were effective, re-
currence was observed in two patients as soon as 
several hours post-BAE. Bleeding control during 
the first 24 hours post-BAE reached the level of 
95.74%. In the course of the long-term observa-
tion, haemoptysis recurrence was reported in 
33.33% of patients. In general, recurrence was 
observed in 56.66% of the subjects. These results 
are in accordance with the outcomes obtained in 
other centres [13–17].
Tape et al. [13] conducted an observation 
on 15 patients with cystic fibrosis in whom 33 
BAEs were performed. The mean time of obser-
vation was 72 months, ranging from 3 to 168 
months. The procedures resulted in 100% of 
haemoptysis inhibition, while recurrence was 
reported in 60% of patients during the whole 
time of observation.
In turn, Shin et al. [14] described a group 
of 398 patients with tuberculosis who under-
went BAE. The reported effectiveness of BAE 
during the first 24 hours was 96.4%, while 
recurrence was observed in 48.6% of patients 
post-BAE. 
Rashad et al. [15] embarked on a study on 
47 patients with massive haemoptysis, who 
were observed for 6 months post-embolisation. 
Re-embolisation was conducted in 2 patients due 
to bleeding recurrence. The following causes of 
haemoptysis were reported: active tuberculosis, 
post-tuberculosis changes in pulmonary paren-
chyma and bronchiectasis. 
Endovascular embolisation is also effective 
in aspergillosis. Corr et al. [16] conducted an 
observation on 12 patients with aspergillosis 
and reported 1 haemoptysis recurrence within 4 
weeks post-BAE.
The effectiveness of endovascular emboli-
sation is high. That notwithstanding, the risk of 
death, lung transplant or pneumonectomy is in-
creased in the group of patients who once suffered 
from haemoptysis, even if they were successfully 
treated with embolization [17].
Vidal et al. [17] compared 30 patients with 
tuberculosis, in whom massive haemoptysis 
was treated with embolisation (42 procedures 
were conducted) to a control group including 
27 healthy patients, matched for sex, age and 
FEV1 value in spirometry. Among patients 
undergoing BAE, haemoptysis was inhibited 
during the first 24 hours in 96.6% (n = 29) 
of cases. A  5-year-long observation showed 
that 9 patients underwent transplantation, in 
comparison to 1 patient in the control group. 
Patients undergoing embolisation due to arte-
rial bleeding are under increased risk of lung 
function deterioration, the need to have a lung 
transplant, or death.
3 out of 30 patients observed in our Depart-
ment required lung transplant (patients with 
tuberculosis), while 1 was in need for right lung 
pneumonectomy (patient with aspergillosis).
Conclusions
Bronchial artery embolisation was highly 
successful shortly after the procedure (95.74% 
during the first 24 hours). Recurrence occurred 
within 1 year in 33.33% of patients, while a sin-
gle re-embolisation was successful in half of the 
sample in the long perspective.
BAE is burdened with a low level of compli-
cations. It can be repeated if needed, including 
once-treated vessels where recanalisation oc-
curred [18].
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